1. [Review of 32 gastro-intestinal stromal tumours with CD117 antigen]
- Author
-
Ahlem, Lahmar-Boufaroua, Sana, Ben Slama, Saadia, Bouraoui, Lassaad, Gharbi, Carole, Goutallier, Saber, Manai, Walid, Gharbi, and Sabah, Mzabi-Regaya
- Subjects
Adult ,Aged, 80 and over ,Male ,Jejunal Neoplasms ,Gastrointestinal Stromal Tumors ,Antineoplastic Agents ,Middle Aged ,Piperazines ,Ileal Neoplasms ,Proto-Oncogene Proteins c-kit ,Pyrimidines ,Treatment Outcome ,Duodenal Neoplasms ,Stomach Neoplasms ,Benzamides ,Biomarkers, Tumor ,Imatinib Mesylate ,Humans ,Female ,Aged ,Retrospective Studies - Abstract
The aim of this study is to review clinical data, histological and immunohistochemical findings and prognosis of stromal gastrointestinal tumors.A retrospective Study of 32 cases of stromal gastrointestinal tumors diagnosed in the Department of Pathology of Mongi Slim Hospital of Tunis from 1991 to 2004.The average age of the patients was of 54.4 years, equal for sex. Tumors were essentially gastric (50%) and of the small intestine (37.5%). All the patients had surgical treatment. Gastro-intestinal Stromal Tumors or GIST represent the most frequent stromal tumor with 56.2% of cases.After immunohistochimestry study, using CD117 antigen, this revision allows better management of GIST. Glivec is the standard treatment of advanced GIST.
- Published
- 2009